Dorzagliatin is a novel oral medication used mainly for treating Type 2 Diabetes Mellitus, approved in China as monotherapy or with metformin, that works by activating glucokinase to improve the body’s glucose control, enhancing insulin secretion and sensitivity, reducing blood sugar, and potentially offering benefits for diabetic kidney disease and even GCK-MODY. It improves HbA1c, fasting, and postprandial glucose levels, and shows promise for restoring pancreatic beta-cell function and halting disease progression in diabetes. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sinogliatin, HuaTangNing and Dorzagliatinum. Its PubChem CID is 57920094.
Dorzagliatin
| CAS No | 1191995-00-2 |
|---|---|
| Molecular Formula | C22H27ClN4O5 |
| Molecular Weight | 462.9 g/mol |
| Synonyms | (2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dorzagliatin is a novel oral medication used mainly for treating Type 2 Diabetes Mellitus, approved in China as monotherapy or with metformin, that works by activating glucokinase to improve the body's glucose control, enhancing insulin secretion and sensitivity, reducing blood sugar, and potentially offering benefits for diabetic kidney disease and even GCK-MODY.
The listed CAS number is 1191995-00-2.
The listed molecular formula is C22H27ClN4O5.
The listed molecular weight is 462.9 g/mol.
(2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide.
The source lists Sinogliatin, HuaTangNing and Dorzagliatinum.